HomeClinical TopicsFDA approves Osphena for postmenopausal women with dyspareunia

FDA approves Osphena for postmenopausal women with dyspareunia

Author(s):

On Feb. 26, 2013, the U.S. Food and Drug Administration (FDA) approved Osphena (ospemifene) to treat women with moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy caused by menopause. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Couple talking to NP

Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could

Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...